Intravenous Magnesium intra-operatively

PreclinicalSmall molecule

Intravenous Magnesium intra-operatively is one of 4 small molecule programs targeting After Cardiac Surgery. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

After Cardiac SurgeryUnknown status

After Cardiac SurgeryPreclinical

Unknown status

Competition

Competitive Landscape

3 competitors in After Cardiac Surgery

#DrugCompanyPhaseTrials

Pituitrin

QQianfoshan Hospital

Preclinical

1 2

Dexmedetomidine /ml

SSt. Justine's Hospital

Preclinical

1 3

Intravenous Magnesium intra-operatively

JJames Cook University Hospital

Preclinical

1 4

Oral Gabapentin Pre-Op

JJames Cook University Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

After Cardiac Surgery1 trial

Enhanced Recovery After Cardiac Surgery

Unknown status·JJames Cook University Hospital·N/A·NCT03859102·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intravenous Magnesium intra-operatively. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intravenous Magnesium intra-operatively compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intravenous Magnesium intra-operatively. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — James Cook University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: JJames Cook University Hospital

Intravenous Magnesium intra-operatively

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

After Cardiac Surgery1 trial

References

Drug Info

Quick Facts

Related News